Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

55.61 -0.43 (-0.77%)
Official Closing Price Updated: 7:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,739,845
Open 55.60
Bid (Size) 55.71 (1)
Ask (Size) 55.82 (3)
Prev. Close 56.04
Today's Range 54.56 - 56.02
52wk Range 45.05 - 125.62
Shares Outstanding N/A
Dividend Yield 3.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit

Performance

YTD
-36.5%
-36.5%
1 Month
-1.5%
-1.5%
3 Month
-18.8%
-18.8%
6 Month
-19.8%
-19.8%
1 Year
-55.3%
-55.3%

More News

Read More
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick
Via Stocktwits
Topics Intellectual Property
Novo Nordisk A/S Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NVO
From DJS Law Group
Via Business Wire
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs
Via Benzinga
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Via Benzinga
Topics Government World Trade
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
Via The Motley Fool
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now
Via The Motley Fool
Topics World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Does This Acquisition Make Pfizer Stock a Great Buy?
Via The Motley Fool
Topics Death Intellectual Property
DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025
From Berger Montague
Via GlobeNewswire
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
Via The Motley Fool
Topics Economy
3 Reasons to Buy Novo Nordisk Stock Right Now
Via The Motley Fool
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
Via Benzinga
Topics ETFs
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Via Investor's Business Daily
Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 55.61
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/26/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.